Kevin T.  Conroy net worth and biography

Kevin Conroy Biography and Net Worth

Kevin Conroy is the Chief Executive Officer, President, and Chairman of the Board of Exact Sciences. He became CEO 11 years ago and he has been part of a team that transformed Exact Sciences into one of the world’s premier cancer diagnostics companies with more than 4,500 employees.

Mr. Conroy has led Exact Sciences through the development, clinical trial, regulatory approval, and commercialization of its noninvasive colorectal cancer screening test, Cologuard®. This culminated with Cologuard becoming the first medical device or diagnostic to receive simultaneous FDA approval and national Medicare coverage. Since 2014, millions of Americans have used Cologuard to screen for colorectal cancer, the second leading cause of cancer death in the United States.

In 2019, Exact Sciences’ acquisition of Genomic Health, Inc., united two of the industry’s strongest brands, Cologuard and Oncotype DX®, and established the company’s position as the global leader in advanced cancer diagnostics. The global company is working to improve screening, early detection, and treatment guidance throughout the cancer continuum.

Before joining Exact Sciences, Mr. Conroy served as CEO and President of Third Wave Technologies, a molecular diagnostics company that developed a breakthrough cervical cancer screening test before being acquired by Hologic in 2008. Mr. Conroy also held leadership positions at GE Healthcare, a global leader in medical imaging and information technology, and practiced intellectual property law in private practice. Mr. Conroy currently serves as a director of Epizyme, Inc. and Adaptive Biotechnology Corporation.

Mr. Conroy is active in the Wisconsin community. He serves as a director of the Greater Madison Chamber of Commerce and on the University of Wisconsin-Madison Chancellor’s Advisory Council. He has also served as chair of The United Way of Dane County’s 2016 annual campaign and as a board member of Overture Center for the Arts.

A native of Flint, Michigan, Mr. Conroy holds a Bachelor of Science degree in electrical engineering from Michigan State University and earned his Juris Doctorate from the University of Michigan Law School.

What is Kevin T. Conroy's net worth?

The estimated net worth of Kevin T. Conroy is at least $66.27 million as of November 13th, 2024. Mr. Conroy owns 1,074,191 shares of Exact Sciences stock worth more than $66,266,843 as of December 2nd. This net worth estimate does not reflect any other investments that Mr. Conroy may own. Additionally, Mr. Conroy receives a salary of $3,140,000.00 as CEO at Exact Sciences. Learn More about Kevin T. Conroy's net worth.

How old is Kevin T. Conroy?

Mr. Conroy is currently 58 years old. There are 6 older executives and no younger executives at Exact Sciences. Learn More on Kevin T. Conroy's age.

What is Kevin T. Conroy's salary?

As the CEO of Exact Sciences Co., Mr. Conroy earns $3,140,000.00 per year. Learn More on Kevin T. Conroy's salary.

How do I contact Kevin T. Conroy?

The corporate mailing address for Mr. Conroy and other Exact Sciences executives is 5505 ENDEAVOR LANE, MADISON WI, 53719. Exact Sciences can also be reached via phone at (608) 284-5700 and via email at [email protected]. Learn More on Kevin T. Conroy's contact information.

Has Kevin T. Conroy been buying or selling shares of Exact Sciences?

Over the course of the past ninety days, Kevin T. Conroy has bought $1,001,325.00 in shares of Exact Sciences stock. Most recently, on Wednesday, November 13th, Kevin T. Conroy bought 19,500 shares of Exact Sciences stock. The stock was acquired at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the transaction, the chief executive officer now directly owns 1,074,191 shares of the company's stock, valued at $55,159,707.85. Learn More on Kevin T. Conroy's trading history.

Who are Exact Sciences' active insiders?

Exact Sciences' insider roster includes Brian Baranick (Insider), Sarah Condella (SVP), Kevin Conroy (CEO), D. Coward (Insider), Everett Cunningham (Insider), James Doyle (Director), Jeffrey Elliott (CFO), James Herriott (General Counsel), Torsten Hoof (Insider), Daniel Levangie (Director), Graham Lidgard (Insider), Jacob Orville (Insider), and Katherine Zanotti (Director). Learn More on Exact Sciences' active insiders.

Are insiders buying or selling shares of Exact Sciences?

In the last twelve months, Exact Sciences insiders bought shares 1 times. They purchased a total of 19,500 shares worth more than $1,001,325.00. In the last twelve months, insiders at the medical research company sold shares 36 times. They sold a total of 77,348 shares worth more than $4,737,043.93. The most recent insider tranaction occured on November, 13th when CEO Kevin T Conroy bought 19,500 shares worth more than $1,001,325.00. Insiders at Exact Sciences own 1.4% of the company. Learn More about insider trades at Exact Sciences.

Information on this page was last updated on 11/13/2024.

Kevin T. Conroy Insider Trading History at Exact Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2024Buy19,500$51.35$1,001,325.001,074,191View SEC Filing Icon  
5/1/2024Sell1,155$60.15$69,473.251,156,191View SEC Filing Icon  
3/1/2024Sell8,271$59.32$490,635.721,299,496View SEC Filing Icon  
2/27/2024Sell6,263$56.89$356,302.071,289,624View SEC Filing Icon  
2/21/2024Sell4,975$61.50$305,962.501,229,756View SEC Filing Icon  
2/15/2024Sell14,791$61.43$908,611.131,224,357View SEC Filing Icon  
2/28/2023Sell10,416$61.12$636,625.921,207,306View SEC Filing Icon  
2/15/2023Sell14,617$65.59$958,729.031,189,620View SEC Filing Icon  
2/13/2023Sell4,527$64.55$292,217.851,173,105View SEC Filing Icon  
7/1/2022Sell7$40.75$285.251,167,927View SEC Filing Icon  
3/1/2022Sell14,299$76.69$1,096,590.31View SEC Filing Icon  
2/23/2022Sell5,188$69.05$358,231.40View SEC Filing Icon  
2/15/2022Sell14,409$79.55$1,146,235.95View SEC Filing Icon  
11/1/2021Sell16,922$93.88$1,588,637.36View SEC Filing Icon  
10/1/2021Sell17,078$93.64$1,599,183.92View SEC Filing Icon  
5/3/2021Sell19,240$131.09$2,522,171.60776,736View SEC Filing Icon  
3/2/2021Sell9,796$138.42$1,355,962.32808,959View SEC Filing Icon  
2/24/2021Sell16,420$136.30$2,238,046.00826,785View SEC Filing Icon  
1/4/2021Sell31,814$128.74$4,095,734.36View SEC Filing Icon  
12/1/2020Sell30,577$124.56$3,808,671.12886,295View SEC Filing Icon  
11/2/2020Sell32,819$121.11$3,974,709.09916,521View SEC Filing Icon  
10/1/2020Sell27,425$103.55$2,839,858.75936,641View SEC Filing Icon  
9/1/2020Sell19,927$75.03$1,495,122.81View SEC Filing Icon  
8/3/2020Sell25,198$93.80$2,363,572.40
2/27/2020Sell13,875$80.27$1,113,746.25986,701View SEC Filing Icon  
2/25/2020Sell18,115$85.11$1,541,767.65984,791View SEC Filing Icon  
3/11/2019Sell11,227$87.21$979,106.67949,753View SEC Filing Icon  
2/27/2019Sell9,169$95.07$871,696.83923,961View SEC Filing Icon  
1/25/2019Sell304,397$81.27$24,738,344.191,190,408View SEC Filing Icon  
11/12/2018Sell163,514$69.00$11,282,466.00886,011View SEC Filing Icon  
3/12/2018Sell11,459$52.19$598,045.21200,074View SEC Filing Icon  
2/26/2018Sell25,319$42.34$1,072,006.46211,183View SEC Filing Icon  
2/9/2018Sell101,488$45.72$4,640,031.36931,540View SEC Filing Icon  
1/23/2018Sell110,439$50.49$5,576,065.11940,491View SEC Filing Icon  
1/12/2018Sell125,402$52.79$6,619,971.58955,454View SEC Filing Icon  
12/22/2017Sell123,512$52.58$6,494,260.96953,564View SEC Filing Icon  
12/6/2017Sell121,849$53.45$6,512,829.05951,901View SEC Filing Icon  
11/21/2017Sell134,057$59.50$7,976,391.50View SEC Filing Icon  
11/9/2017Sell137,805$59.14$8,149,787.70967,867View SEC Filing Icon  
3/13/2017Sell12,059$21.16$255,168.44817,239View SEC Filing Icon  
11/15/2016Sell600,000$17.46$10,476,000.001,340,057View SEC Filing Icon  
3/1/2016Buy50,000$5.00$250,000.00687,907View SEC Filing Icon  
2/26/2016Sell6,895$5.81$40,059.95637,907View SEC Filing Icon  
2/23/2016Sell6,866$6.39$43,873.74632,168View SEC Filing Icon  
2/26/2015Sell8,425$23.44$197,482.00View SEC Filing Icon  
2/24/2015Sell9,798$22.90$224,374.20View SEC Filing Icon  
1/2/2015Sell9,484$26.72$253,412.48View SEC Filing Icon  
7/25/2014Sell11,336$15.99$181,262.64View SEC Filing Icon  
11/2/2012Buy2,000$9.13$18,260.00View SEC Filing Icon  
See Full Table

Kevin T. Conroy Buying and Selling Activity at Exact Sciences

This chart shows Kevin T Conroy's buying and selling at Exact Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Exact Sciences Company Overview

Exact Sciences logo
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Read More

Today's Range

Now: $61.11
Low: $60.98
High: $62.26

50 Day Range

MA: $63.85
Low: $49.33
High: $71.93

2 Week Range

Now: $61.11
Low: $40.62
High: $79.62

Volume

356,169 shs

Average Volume

2,638,128 shs

Market Capitalization

$11.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24